| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Departments of 1 Pathology, 2 Radiation Oncology, 3 Internal Medicine, 4 Surgery, and 5 Environmental and Occupational Health and Institutes of 6 Molecular Medicine, College of Medicine, National Cheng Kung University, and7 Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan
Requests for reprints: Wen-Ying Lee, Department of Pathology, Chi Mei Medical Center, 901 Chung Hwa Road, Yung Kang City, Tainan 710, Taiwan. Fax: 886-6-2746411; E-mail: 7707{at}so-net.net.tw.
Purpose: RON and MET belong to a subfamily of tyrosine kinase receptors. They both can induce invasive growth, including migration, cell dissociation, and matrix invasion. Cross-linking experiments show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling. We wanted to examine the clinical significance of RON and MET expression patterns in node-negative breast cancer.
Experimental Design: We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-year follow-up.
Results: Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET. The MCF-7 cell line did not express RON or MET. In multiple logistic regression analysis, RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse. RON+/MET+ and RON–/MET+ tumors resulted in a large risk increase for 10-year disease-free survival after adjusting for tumor size, histologic grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox analysis (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005). The 10-year disease-free survival was 79.3% in patients with RON–/MET– tumors, was only 11.8% in patients with RON+/MET+ tumors, and was 43.9% and 55.6% in patients with RON–/MET+ and RON+/MET– tumors.
Conclusions: Co-expression of RON and MET seems to signify an aggressive phenotype in node-negative breast cancer patients.
Key Words: RON • MET • node-negative breast cancer • Tumor Progression, Invasion, and Metastasis • Breast cancer
This article has been cited by other articles:
|
|
 |
|
  M. Narasimhan and S. Ammanamanchi Curcumin Blocks RON Tyrosine Kinase-Mediated Invasion of Breast Carcinoma Cells Cancer Res., July 1, 2008; 68(13): 5185 - 5192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thangasamy, J. Rogge, and S. Ammanamanchi Regulation of RON Tyrosine Kinase-mediated Invasion of Breast Cancer Cells J. Biol. Chem., February 29, 2008; 283(9): 5335 - 5343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Thomas, K. Toney, C. Fenoglio-Preiser, M. P. Revelo-Penafiel, S. R. Hingorani, D. A. Tuveson, S. E. Waltz, and A. M. Lowy The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression Cancer Res., July 1, 2007; 67(13): 6075 - 6082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Welm, J. B. Sneddon, C. Taylor, D. S. A. Nuyten, M. J. van de Vijver, B. H. Hasegawa, and J. M. Bishop The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans PNAS, May 1, 2007; 104(18): 7570 - 7575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Shattuck, J. K. Miller, M. Laederich, M. Funes, H. Petersen, K. L. Carraway III, and C. Sweeney LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy Mol. Cell. Biol., March 1, 2007; 27(5): 1934 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Zinser, M. A. Leonis, K. Toney, P. Pathrose, M. Thobe, S. A. Kader, B. E. Peace, S. R. Beauman, M. H. Collins, and S. E. Waltz Mammary-Specific Ron Receptor Overexpression Induces Highly Metastatic Mammary Tumors Associated with {beta}-Catenin Activation Cancer Res., December 15, 2006; 66(24): 11967 - 11974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hiscox, N. J Jordan, W. Jiang, M. Harper, R. McClelland, C. Smith, and R. I Nicholson Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions Endocr. Relat. Cancer, December 1, 2006; 13(4): 1085 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. O'Toole, K. E. Rabenau, K. Burns, D. Lu, V. Mangalampalli, P. Balderes, N. Covino, R. Bassi, M. Prewett, K. J. Gottfredsen, et al. Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member. Cancer Res., September 15, 2006; 66(18): 9162 - 9170. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
